GoodRx Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $796.9M | $792.3M | $750.3M | $766.6M | $745.4M |
| Operating income | $87.5M | $65.8M | -$27.0M | $1.7M | $13.4M |
| Cash from operations | $167.9M | $183.9M | $138.3M | $146.8M | $178.8M |
| Capital expenditure | $3.5M | $1.2M | $1.0M | $4.0M | $4.6M |
| Free cash flow | $164.4M | $182.7M | $137.2M | $142.8M | $174.2M |
| Share repurchases | $216.4M | $158.8M | $104.0M | $101.7M | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.4B | $1.4B | $1.6B | $1.6B | $1.6B |
| Total liabilities | $787.8M | $663.4M | $826.8M | $789.8M | $775.9M |
Shares outstanding 338.7M · Free float 52.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.